Plasma Oxytocin Changes in Response to Low-dose MDMA vs. Placebo in Patients With Arginine Vasopressin Deficiency and Healthy Controls (OxyMAX)

Randomized, double-blind, placebo-controlled crossover (two sessions, washout ≥10 days) testing single low doses of MDMA (25 mg or 50 mg) versus placebo in patients with arginine vasopressin deficiency and matched healthy controls.

Primary outcome is change in plasma oxytocin; study will confirm prior findings and provide safety data for low-dose MDMA stimulation testing, with monitoring of vitals and adverse events.